Kindred Biosciences Inc. (KIN) 7.45 $KIN
The Growing Business Of Animal Healthcare
Value Line - Seeking Alpha - Tue Apr 14, 7:44AM CDT
By George M. Lee Despite an uneven economic recovery, demand for higher-quality animal healthcare continues to increase. Veterinary spending on pets has grown at a steady clip in recent years and ought to remain strong. Meanwhile many farmers...
VRX: 206.93 (-3.92), PAHC: 33.44 (+1.09), PFE: 34.93 (+0.04), WMT: 78.43 (+0.40), PDCO: 47.34 (+0.13), PETX: 16.15 (+0.01), LLY: 72.30 (+0.09), KIN: 7.45 (+0.25), ZTS: 47.03 (-0.51), ABC: 113.81 (-0.08), MWIV: 190.00 (+0.10), ABAX: 63.25 (-0.09), MRK: 57.69 (+0.03), ICCC: 6.32 (+0.19), TGT: 81.34 (+0.09), IDXX: 155.97 (+0.75), WOOF: 55.13 (-0.18), HSIC: 141.11 (+1.14), NVS: 103.45 (-0.62), PETM: 82.98 (+0.03)
Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit
PR Newswire - Thu Mar 19, 8:20AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will be presenting at the 2015 Jefferies Animal Health Summit in New York, NY on Thursday, March 26, 2015 at 1:30 PM EDT.
KIN: 7.45 (+0.25)
Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of Fever in Horses
PR Newswire - Mon Mar 16, 3:02PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses.
KIN: 7.45 (+0.25)
Kindred Biosciences' (KIN) CEO Richard Chin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 6:35PM CDT
KIN: 7.45 (+0.25)
Kindred Bio reports 4Q loss
Automated Insights - Thu Mar 12, 4:43PM CDT
SAN FRANCISCO (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $6.8 million in its fourth quarter.
KIN: 7.45 (+0.25)
Kindred Biosciences beats by $0.09
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:14PM CDT
KIN: 7.45 (+0.25)
Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results
PR Newswire - Thu Mar 12, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014.
KIN: 7.45 (+0.25)
KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results
PR Newswire - Tue Mar 03, 7:30AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
KIN: 7.45 (+0.25)
Seeking Baupost: The Hidden Holdings - Part III
Matthew Finston - at Seeking Alpha - Sat Feb 28, 5:35AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), TBPH: 18.41 (+0.18), THRX: 17.08 (+0.45), VRTV: 41.62 (+1.04), IMOS: 24.00 (+0.47), GLNG: 35.48 (+0.87), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32)
Seeking Baupost: The Himalayan Yeti Frightens
Matthew Finston - at Seeking Alpha - Tue Feb 24, 7:49AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), FWP: 31.77 (-0.66), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Seeking Baupost: The Pangs Of Value Investing - Part 1
Matthew Finston - at Seeking Alpha - Mon Feb 16, 9:28AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), BYD: 13.17 (+0.16), AVEO: 2.04 (+0.12), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Tracking Seth Klarman's Baupost Group Holdings - Q4 2014 Update
John Vincent - at Seeking Alpha - Sun Feb 15, 1:07AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), QRVO: 74.48 (+0.41), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32), SUNE: 27.27 (+0.56), AIG: 56.58 (-0.06)
Kindred Biosciences: Unique Veterinary Drug Company Trading At 1.2 Times Net Cash
Mark Lin - at Seeking Alpha - Wed Feb 04, 9:37AM CST
KIN: 7.45 (+0.25)
Will Kindred Biosciences (KIN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:21AM CST
Will Kindred Biosciences (KIN) Continue to Surge Higher?
KIN: 7.45 (+0.25)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), ATRA: 63.79 (+7.64), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), PRTK: 28.96 (+0.61), KIN: 7.45 (+0.25), KERX: 11.52 (-0.15)
Kindred Biosciences (KIN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:33AM CST
Kindred Biosciences (KIN) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions, and is a great company from a Zacks Industry Rank perspective.
KIN: 7.45 (+0.25)
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:18AM CST
Kindred Biosciences, Inc. (KIN) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
BIIB: 423.57 (+1.46), ANIP: 69.79 (+1.24), KIN: 7.45 (+0.25), AFFX: 12.57 (-0.13)
Kindred Bio exits atopic dermatitis, shares drop
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:24AM CST
KIN: 7.45 (+0.25)
KindredBio Announces Update on AtoKin and Atopic Dermatitis Program
PR Newswire - Wed Dec 03, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
KIN: 7.45 (+0.25)
The Growing Business Of Animal Healthcare
Value Line - Seeking Alpha - Tue Apr 14, 7:44AM CDT
By George M. Lee Despite an uneven economic recovery, demand for higher-quality animal healthcare continues to increase. Veterinary spending on pets has grown at a steady clip in recent years and ought to remain strong. Meanwhile many farmers...
VRX: 206.93 (-3.92), PAHC: 33.44 (+1.09), PFE: 34.93 (+0.04), WMT: 78.43 (+0.40), PDCO: 47.34 (+0.13), PETX: 16.15 (+0.01), LLY: 72.30 (+0.09), KIN: 7.45 (+0.25), ZTS: 47.03 (-0.51), ABC: 113.81 (-0.08), MWIV: 190.00 (+0.10), ABAX: 63.25 (-0.09), MRK: 57.69 (+0.03), ICCC: 6.32 (+0.19), TGT: 81.34 (+0.09), IDXX: 155.97 (+0.75), WOOF: 55.13 (-0.18), HSIC: 141.11 (+1.14), NVS: 103.45 (-0.62), PETM: 82.98 (+0.03)
Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit
PR Newswire - Thu Mar 19, 8:20AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will be presenting at the 2015 Jefferies Animal Health Summit in New York, NY on Thursday, March 26, 2015 at 1:30 PM EDT.
KIN: 7.45 (+0.25)
Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of Fever in Horses
PR Newswire - Mon Mar 16, 3:02PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses.
KIN: 7.45 (+0.25)
Kindred Biosciences' (KIN) CEO Richard Chin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 6:35PM CDT
KIN: 7.45 (+0.25)
Kindred Bio reports 4Q loss
Automated Insights - Thu Mar 12, 4:43PM CDT
SAN FRANCISCO (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $6.8 million in its fourth quarter.
KIN: 7.45 (+0.25)
Kindred Biosciences beats by $0.09
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:14PM CDT
KIN: 7.45 (+0.25)
Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results
PR Newswire - Thu Mar 12, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014.
KIN: 7.45 (+0.25)
KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results
PR Newswire - Tue Mar 03, 7:30AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
KIN: 7.45 (+0.25)
Seeking Baupost: The Hidden Holdings - Part III
Matthew Finston - at Seeking Alpha - Sat Feb 28, 5:35AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), TBPH: 18.41 (+0.18), THRX: 17.08 (+0.45), VRTV: 41.62 (+1.04), IMOS: 24.00 (+0.47), GLNG: 35.48 (+0.87), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32)
Seeking Baupost: The Himalayan Yeti Frightens
Matthew Finston - at Seeking Alpha - Tue Feb 24, 7:49AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), FWP: 31.77 (-0.66), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Seeking Baupost: The Pangs Of Value Investing - Part 1
Matthew Finston - at Seeking Alpha - Mon Feb 16, 9:28AM CST
ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), PBF: 29.60 (+0.40), OCN: 7.68 (+0.14), NCQ: 0.61 (unch), LNG: 78.61 (+1.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), BXE: 3.13 (unch), AOI: 1.46 (+0.08), EBAY: 56.75 (+0.33), ALDW: 19.87 (+0.32), BYD: 13.17 (+0.16), AVEO: 2.04 (+0.12), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47)
Tracking Seth Klarman's Baupost Group Holdings - Q4 2014 Update
John Vincent - at Seeking Alpha - Sun Feb 15, 1:07AM CST
OCN: 7.68 (+0.14), PRTK: 28.96 (+0.61), KOS: 8.48 (-0.02), KIN: 7.45 (+0.25), VSAT: 62.14 (-0.45), BXE: 3.13 (unch), EBAY: 56.75 (+0.33), SEMI: 24.23 (+0.04), VRTV: 41.62 (+1.04), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), IMOS: 24.00 (+0.47), ELOS: 12.19 (-0.10), MU: 29.50 (+0.95), AR: 41.95 (+0.57), NCQ: 0.61 (unch), PBF: 29.60 (+0.40), LNG: 78.61 (+1.61), ATRA: 63.79 (+7.64), KERX: 11.52 (-0.15), NG: 3.56 (-0.07), AOI: 1.46 (+0.08), QRVO: 74.48 (+0.41), FWP: 31.77 (-0.66), ALDW: 19.87 (+0.32), SUNE: 27.27 (+0.56), AIG: 56.58 (-0.06)
Kindred Biosciences: Unique Veterinary Drug Company Trading At 1.2 Times Net Cash
Mark Lin - at Seeking Alpha - Wed Feb 04, 9:37AM CST
KIN: 7.45 (+0.25)
Will Kindred Biosciences (KIN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:21AM CST
Will Kindred Biosciences (KIN) Continue to Surge Higher?
KIN: 7.45 (+0.25)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 423.57 (+1.46), FWP: 31.77 (-0.66), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), ATRA: 63.79 (+7.64), THRX: 17.08 (+0.45), TBPH: 18.41 (+0.18), PRTK: 28.96 (+0.61), KIN: 7.45 (+0.25), KERX: 11.52 (-0.15)
Kindred Biosciences (KIN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:33AM CST
Kindred Biosciences (KIN) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions, and is a great company from a Zacks Industry Rank perspective.
KIN: 7.45 (+0.25)
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:18AM CST
Kindred Biosciences, Inc. (KIN) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
BIIB: 423.57 (+1.46), ANIP: 69.79 (+1.24), KIN: 7.45 (+0.25), AFFX: 12.57 (-0.13)
Kindred Bio exits atopic dermatitis, shares drop
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:24AM CST
KIN: 7.45 (+0.25)
KindredBio Announces Update on AtoKin and Atopic Dermatitis Program
PR Newswire - Wed Dec 03, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
KIN: 7.45 (+0.25)
